 |
At Avila, we are committed to communicating clear and consistent information; here we feature current and historic content concerning our science, our pipeline and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Press Releases & Media Coverage
| 3/10/10 |
Avila Presents at Cowen and Company 30th Annual Healthcare Conference |
| 2/26/10 |
xConomy: "Avila Aims to Trump Vertex With Drug that Hits Hepatitis C Virus and Won't Let Go" |
| 2/12/2010 |
Pharmawire: "Avila Therapeutics to Advance Lead Covalent Drug Programs to Clinic this Year" |
1/28/10 |
BIO-IT WORLD.COM: "Avila Therapeutics Targets the Covalent Proteome" |
| 11/02/09 |
Avila Presents Data on its Novel, Orally-Available Protease Inhibitor AVL-181, Demonstrating Viral Clearance of Hepatitis C Virus in Preclinical Models |
10/5/09 |
Avila Presents Preclinical Data on its Novel, Orally-Available, Pan-Genotype Protease Inhibitor, AVL-181, Demonstrating Protein Silencing of Hepatitis C Virus |
| 9/25/09 |
EP Vantage: "Avila covalent drugs looking highly attractive" |
| 9/01/09 |
Drug Discovery News: "Novartis sponsors Avila Therapeutics' covalent drug candidate" |
| 7/28/09 |
BioWorld: "Avila Raises $30M, Pulls Down $200M deal with Novartis Fund" |
| 7/27/09 |
Avila Therapeutics, Inc. Closes $30 Million Series B Financing |
| 7/27/09 |
Avila Therapeutics Announces Agreement with Novartis to Develop Novel Covalent Drug Candidate |
| 5/15/09 |
Avila Therapeutics Appoints Katrine S. Bosley as Company’s First CEO |
| 4/25/09 |
Avila Presents Preclinical Data on Novel, Orally-Available, Protease Inhibitor, AVL181, for Hepatitis C Infection at EASL 2009 Meeting |
| 4/27/09 |
xConomy: "Avila Therapeutics May Have Found Achilles Heel of Hepatitis C Virus" |
| 4/21/09 |
Avila Presents Data on Novel, Orally-Available, Covalent Drugs Targeting Btk and ErbB Receptors, and Innovative Translation Technology, at Annual AACR Meeting |
| 12/8/08 |
xConomy: "Avila Comes Out of Stealth to Talk Bonds, Covalent Bonds" |
| 12/7/08 |
Avila Presents Data on Novel Btk Inhibitor, AVL-101, for B Cell Malignancies at the Annual Meeting of the American Society of Hematology |
| 12/5/08 |
Avila Therapeutics Appoints Daniel S. Lynch as Executive Chairman |
All PDFs require the Adobe Reader. If you are unable to open the linked press releases, download the Adobe Reader.
|
|
